OLMA
HEALTHCAREOlema Pharmaceuticals Inc
$15.19+0.55 (+3.76%)PRE
Live · NASDAQ · May 9, Close
AI Insight
What's Moving OLMA Today?
No stock-specific AI insight has been generated for OLMA yet. Check back soon — insights are generated from recent news analysis.
52-Week Range
$3.89$36.26
$15.19
Fundamentals
Market Cap$1.3B
P/E Ratio—
EPS$-1.87
Dividend Yield—
Dividend / Share—
ROE-0.4%
Profit Margin—
Debt / Equity—
Trading
Volume562K
Avg Volume (10D)—
Shares Outstanding87.3M
OLMA News
20 articles- Olema Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)Yahoo Finance·May 4, 2026
- Olema Oncology Appoints Prakash Raman, Ph.D., to Board of DirectorsYahoo Finance·Apr 29, 2026
- Olema Oncology to Present Initial Clinical Data for OP-3136 at the 2026 ASCO Annual MeetingYahoo Finance·Apr 21, 2026
- Olema Oncology Announces Preclinical Data for Palazestrant and OP-3136 at the 2026 AACR Annual MeetingYahoo Finance·Apr 17, 2026
- Jim Cramer on Olema Pharmaceuticals: “Too Risky for Me”Yahoo Finance·Mar 24, 2026
- Olema Shelf Registration Raises Questions On Dilution And Funding FlexibilityYahoo Finance·Mar 23, 2026
- Olema Stock Up 242%, but Does a $122 Million Position Suggest More Upside Potential?Motley Fool·Mar 22, 2026
- Olema Pharmaceuticals (OLMA) Loses 33.4% in 4 Weeks, Here's Why a Trend Reversal May be Around the CornerYahoo Finance·Mar 18, 2026
- Olema Oncology to Present Preclinical Data for Palazestrant and OP-3136 at the 2026 AACR Annual MeetingYahoo Finance·Mar 17, 2026
- Biotech Stock Up Nearly 300% Draws $68.7 Million Bet as Breast Cancer Drug Targets 2027 LaunchMotley Fool·Mar 16, 2026
- Exchange-Traded Funds, Equity Futures Higher Pre-Bell Monday as Investors Weigh Tech Rally Against Geopolitical RisksYahoo Finance·Mar 16, 2026
- Olema Oncology Reports Fourth Quarter and Full Year 2025 Financial and Operating ResultsYahoo Finance·Mar 16, 2026
- A Look At Olema Pharmaceuticals (OLMA) Valuation After Roche Breast Cancer Trial Setback And Share Price PullbackYahoo Finance·Mar 13, 2026
- H.C. Wainwright does not see direct read from Roche miss to Olema’s OPERA-02Yahoo Finance·Mar 10, 2026
- Roche Tumbles, Taking Olema With It, On A High-Profile FailureYahoo Finance·Mar 9, 2026
- Olema Pharmaceuticals CEO Touts Palazestrant Edge as Oral SERDs Shake Out at ConferenceMarketbeat·Mar 1, 2026
- How Leadership Turnover During Key Trial Milestones Will Impact Olema Pharmaceuticals (OLMA) InvestorsYahoo Finance·Feb 28, 2026
- Citi, Stifel Bullish on Olema (OLMA) Despite COO DepartureYahoo Finance·Feb 27, 2026
- Protagonist Stock Up 120%, but One Fund Just Revealed a $170 Million ExitMotley Fool·Feb 25, 2026
- Disc Medicine Stock Is Swinging, but This Fund's New $52 Million Bet Shows ConvictionMotley Fool·Feb 25, 2026
All 20 articles loaded
Price Data
Open$14.67
Previous Close$14.64
Day High$15.30
Day Low$14.50
52 Week High$36.26
52 Week Low$3.89
52-Week Range
$3.89$36.26
$15.19
Fundamentals
Market Cap$1.3B
P/E Ratio—
EPS$-1.87
Dividend Yield—
Dividend / Share—
ROE-0.4%
Profit Margin—
Debt / Equity—
Trading
Volume562K
Avg Volume (10D)—
Shares Outstanding87.3M
About Olema Pharmaceuticals Inc
Olema Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapies for women's cancers. The company is headquartered in San Francisco, California.
HEALTHCAREBIOTECHNOLOGY
Company Details
Security TypeStock
ExchangeNASDAQ
CurrencyUSD
Round Lot—
SICBIOTECHNOLOGY
CIK—
Composite FIGI—
Share Class FIGI—